Compare DexCom, Inc. (DXCM) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Under Armour Inc Class A — how do they compare? DexCom, Inc. trades at $77.89 (market cap $28.06B), while Under Armour Inc Class A trades at $7.27 (market cap $2.89B). The key difference: DexCom, Inc. is far larger — about 9.7× Under Armour Inc Class A's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | UAA | |
|---|---|---|
Market Cap | $28.06B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $8.14 |
52-Week Low | $54.84 | $4.17 |
Enterprise Value | $27.03B | $4.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Under Armour (UAA) trades at $6.61, down 2.07% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion, though recent quarters have shown some earnings beats. The stock is trading above the consensus price target of $5.96, with analyst sentiment leaning toward Hold.
The outlook remains challenging due to weak North American sales and margin pressure, but international growth and a new Dodge collaboration offer potential catalysts. Key risks include persistent revenue declines, high debt levels, and competitive pressures. Investors should weigh the company's brand strength against ongoing operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
